Side Effect Reporting can be found at the bottom of this page
This website is intended for members of the public
For UK healthcare professionals.
The information on this site is intended for UK healthcare professionals only. If you are a healthcare professional looking to find out more about EYLEA® (aflibercept), please It is recommended that you close your browser after you have finished viewing the site.
For members of the public
If you are not a healthcare professional and you want to learn about EYLEA® (aflibercept) pleasePP-EYL-GB-0749
Date of preparation: May 2021
Brand Navigation Banner - Sub Brand Theme B
Main navigation B
For UK healthcare professionals
The information on this site is intended for UK healthcare professionals only. If you are a healthcare professional, please It is recommended that you close your browser after you have finished viewing the site. This website contains promotional material.
For members of the public
If you are not a healthcare professional, pleasePP-EYL-GB-1697
Date of preparation: May 2023
We recommend that you use the latest version of your web browser for the best experience on eylea.co.uk.
Copyright © 2024, Bayer plc
This website has been developed and fully funded by Bayer plc. The health information on this website is intended as general information and for a UK audience only. It is not intended to replace a consultation with a healthcare professional. Always speak to a qualified healthcare professional for personal medical advice.
PP-EYL-GB-2056 | January 2024
EYLEA® (aflibercept) 8 mg:
Great Britain Summary of Product Characteristics (SmPC)
Great Britain Patient Information Leaflet (PIL)
EYLEA® (aflibercept) 2 mg:
Copyright © 2024, Bayer plc
This website has been developed and fully funded by Bayer plc. The health information on this website is intended as general information and for a UK audience only. It is not intended to replace a consultation with a healthcare professional. Always speak to a qualified healthcare professional for personal medical advice.
PP-EYL-GB-2056 | January 2024
